Clinic
Pedsplus Urgent Care, LLC
Pedsplus Urgent Care, LLC was paid $11.03M by Medicaid between Jan 2018 and Dec 2024, across 65 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 17% of everything it billed.
33Billing provider infoPEDSPLUS URGENT CARE, LLC
FREDERICKSBURG, VA 22401
FREDERICKSBURG, VA 22401
33aNPI1275087553assigned 08/04/2016
33bProvider typeUrgent Care Clinic/Center
28Total paid$11.03M
24GClaims301,246
24DCodes billed65
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Virginia
Rank by total paid#5 of 51
Median peer was paid$182K
This provider vs. median61×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,201 | $153K | |
| 2019 | 9,579 | $370K | |
| 2020 | 6,614 | $255K | |
| 2021 | 49,779 | $1.50M | |
| 2022 | 97,006 | $3.07M | |
| 2023 | 86,201 | $3.46M | |
| 2024incomplete | 47,866 | $2.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 24,327 | 20,660 | $1.87M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 13% | 24,287 | 19,055 | $1.42M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 11% | 16,896 | 14,616 | $1.18M |
| 87634 | 8.8% | 16,877 | 14,600 | $972K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.7% | 15,605 | 13,488 | $846K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.4% | 7,178 | 6,470 | $703K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 6.1% | 12,983 | 10,390 | $675K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.9% | 21,475 | 17,888 | $541K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.5% | 13,656 | 11,752 | $386K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.3% | 1,409 | 1,231 | $367K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.1% | 7,738 | 6,866 | $342K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.8% | 4,707 | 4,306 | $307K |
53 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.1% | 42,922 | $231K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.9% | 12,971 | $213K |
| 87581 | 1.7% | 6,788 | $187K | |
| 87486 | 1.7% | 6,776 | $187K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 13,619 | $132K |
| 87481 | 1.1% | 1,242 | $124K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,222 | $62K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,635 | $50K |
| 87631 | <1% | 631 | $36K | |
| 87640 | <1% | 1,318 | $35K | |
| 87653 | <1% | 1,229 | $33K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,195 | $25K |
| 99050 | <1% | 8,463 | $24K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,697 | $23K |
| 87500 | <1% | 845 | $21K | |
| 99072 | <1% | 14,304 | $8K | |
| 87807 | <1% | 827 | $6K | |
| 81002 | <1% | 2,272 | $5K | |
| 99401 | <1% | 231 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 105 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 100 | $2K |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 1,375 | $2K |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 1,366 | $1K |
| 90686 | <1% | 99 | $1K | |
| 81025 | <1% | 181 | $1K | |
| 99173 | <1% | 754 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 28 | $887.63 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 89 | $857.19 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 318 | $655.14 |
| 93000 | <1% | 63 | $606.34 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $568.93 |
| 90619 | <1% | 21 | $556.29 | |
| 87541 | <1% | 14 | $500.36 | |
| 92551 | <1% | 57 | $287.14 | |
| 94760 | <1% | 600 | $273.02 | |
| 87529 | <1% | 20 | $249.13 | |
| 90715 | <1% | 12 | $246.89 | |
| 90713 | <1% | 24 | $229.58 | |
| 90707 | <1% | 18 | $199.06 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 124 | $196.07 |
| 90700 | <1% | 20 | $174.13 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 38 | $164.38 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,158 | $153.86 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 286 | $150.32 |
| 90461 | <1% | 94 | $141.66 | |
| 90716 | <1% | 18 | $121.00 | |
| 87511 | <1% | 21 | $107.37 | |
| 99001 | <1% | 244 | $82.76 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,187 | $79.46 |
| 96160 | <1% | 14 | $15.89 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 49 | $9.15 |
| H0033 | Oral medication administration, direct observation | <1% | 12 | $7.00 |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | 0% | 397 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAURORE, MICKELINA (MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Centercare Family Practice, LLC | Fredericksburg, VA | $2.99M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.